Clinical trials of P-glycoprotein reversal in solid tumours

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1070-1081

  Ferry, D R ^a   Traunecker, H ^a   Kerr, D J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; 9,10 DIHYDRO 5 METHOXY 9 OXO N [4 [2 (1,2,3,4 TETRAHYDRO 6,7 DIMETHOXY 2 ISOQUINOLINYL)ETHYL]PHENYL] 4 ACRIDINECARBOXAMIDE; AMIODARONE; BEPRIDIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXNIGULDIPINE; DEXVERAPAMIL; DOXORUBICIN; ELACRIDAR; EPIRUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MIDOSTAURIN; NIFEDIPINE; QUINIDINE; QUININE; TAMOXIFEN; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VERAPAMIL DERIVATIVE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG PROTEIN BINDING; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; TREATMENT OUTCOME;

CLINICAL TRIALS; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; QUINOLINES; TAMOXIFEN; VERAPAMIL;

EID: 0030001001     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00091-3     Document Type: Article

References (119)

1. Gottesman MM, Pastan P. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993, 62, 385-427.
2. Adams DJ, Knick VC. MDR and non-MDR forms of cellular resistance to 5′-noranhydrovinblastine (navelbine). Proc Annu Meet Am Assoc Cancer Res 1992, 33, A2760.
3. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993, 5, 467-474.
4. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT. Essential features of the P-glycoprotein pharmacophore as denned by a series of reserpine analogues that modulate multidrug resistance. Proc Natl Acad Sci USA 1989, 86, 5128-5132.
5. Endicott JA, Ling V. The biochemistry of multidrug resistance. Ann Rev Biochem 1989, 58, 137-171.
6. Grindley GB. Current status of cancer drug development. Cancer Cells 1990, 2, 163-171.
7. Woodhouse JR, Ferry DR. The genetic basis of resistance to cancer chemotherapy: opening potential therapeutic avenues. Ann Int Med 1994, 27, 157-167.
8. Tolcher AW, Cowan KH, Solomon D, et al. A phase I study of paclitaxel (T) with r-verapamil (RV) in metastatic breast cancer (MBC). Proc Ann MtgAm Soc Clin Oncol 1994, 13, A349.
9. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese Hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 1970, 30, 1174-1184.
10. Chen G, Jaffrezou J, Fleming WH, Duran GE, Sikic BI. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 1994, 54, 4980-4987.
11. Tsuruo T, Tsukagoshi S, Sakurai Y. Overcoming vincristine resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41, 1967-1972.
12. Lee JS, Paull K, Alvarez M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994, 46, 627-638.
13. Tang WD, Kajiji S, Di Capua F, de Graaf D, Roninson IB, Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995, 34, 32-39.
14. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from multidrug resistant cells. Proc Natl Acad Sci USA 1988, 85, 3580-3584.
15. Ferry DR, Russell MA, Cullen MH. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca alkaloid-selective binding site. Biochem Biophys Res Commun 1992, 188, 440-445.
16. Cantwell B, Buamah P, Harris AL. Phase I and II study of oral verapamil and intravenous vindesine. Proc Am Soc Clin Oncol 1985, 42, 161.
17. Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991, 83, 105-110.
18. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 1991, 9, 17-24.
19. Kerr DJ, Graham J, Cummings J, et al. The effects of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986, 18, 239-242.
20. Mross K, Hamm D, Hossfeld K. Effects of verapamil on pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 1993, 31, 369-375.
21. Woodcock BG, Schultz WS, Kuber G. Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther 1981, 30, 52-61.
22. Saltz L, Murphy B, Kemeny N, et al. A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer 1994, 74, 2757-2764.
23. Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer 1993, 68, 813-18.
24. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992, 43, 109-117.
25. Kronbach T, Fischer V, Meyer UA. Cyclosporin metabolism in human liver: identification of a cytochrome P-450 gene family as the major cyclosporin metabolising enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 1988, 43, 630-635.
26. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994, 12, 835-842.
27. Fisher GA, Bartlett NL, Lum BL, et al. Phase I trial of Taxol (T) with high-dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR) (meeting abstract). Proc Ann Mtg Am Soc Clin Oncol 1994 13, A369.
28. Columbo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Ther 1994, 269, 22-26.
29. Ehrlichman C, Moore M, Theissen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993, 35, 4837-4842.
30. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukaemia. J Clin Oncol 1993, 11, 1652-1660.
31. Bachaur NR. Adriamycin (NSC-123127) pharmacology. Cancer Chemother Rep 1975, 6, 153-158.
32. Augustine JA, Zematis MA. The effects of cyclosporin A (CsA) on hepatic microsomal drug metabolism in the rat. Drug Metab Disp 1986, 14, 73-78.
33. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug resistant myeloma by cyclosporin. Lancet 1992, 340, 255-258.
34. Rodenberg CJ, Nooter K, Herweijer H, Seynaeve R, Stoter G, Verweij J. Phase II study combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991, 2, 305-306.
35. Kim JH, Chung JB, Park IS, et al. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Yonsei Med J 1993, 34, 35-44.
36. Samuels BL, O'Brien SM, Vogelzang NJ, et al. Phase I trial of double modulation of multidrug resistance (MDR) with cyclosporin A (CSA) and tamoxifen (TAM) (meeting abstract). Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A450.
37. Tsuruo T, Lida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug resistant tumour cells. Cancer Res 1984, 44, 4303-4307.
38. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 1992, 28, 28-31.
39. Jones RD, Kerr DJ, Harnett AN, et al. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 1990, 62, 133-135.
40. Fardel O, Lecureur V, Guillouzo A. Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 1993, 327, 189-193.
41. Verrelle P, Meissonnier F, Fonk Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991, 83, 111-116.
42. Wigler PW, Patterson FK. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta 1994, 1189, 1-6.
43. Solary E, Velay I, Chauffert B, et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/adm. Cancer 1991, 68, 1714-1719.
44. Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992, 10, 1730-1736.
45. Schuller J, Czejka M, Bandak S, Micksche M. Epirubicin (E) pharmacokinetics (PK) (1) in serum (S) and RBC and (2) influenced by quinine (Q) (meeting abstract). Proc Ann Mtg Am Assoc Cancer Res 1993, 34, A1270.
46. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991, 77, 348-354.
47. Cole MP, Jones CTA, Todd IDH. A new antioestrogenic agent in late breast cancer. An early appraisal of ICI 46,474. Br J Cancer 1971, 25, 270-275.
48. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994, 48, 287-292.
49. Stuart NS, Philip P, Harris AL, et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br J Cancer 1992, 66, 833-839.
50. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992, 84, 1811-1816.
51. Samuels BL, Trump DL, Rosner G, et al. Multidrug resistance (MDR) modulation in renal cell carcinoma (RCC) using cyclosporine A (CSA) or tamoxifen (TAM) (CALGB 9163). Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A793.
52. Smith DC, Trump DL. A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother Pharmacol 1995, 36, 65-68.
53. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985, 45, 2462-2465.
54. Sampson E, Wolff CL, Abraham I. Staurosporine reduces P-glycoprotein expression and modulates drug resistance. Cancer Lett 1993, 68, 78-82.
55. Kiss Z, Crilly KS. Tamoxifen inhibits uptake and metabolism of ethanolamine and choline in multidrug-resistant, but not in drug-sensitive, MCF-7 human breast carcinoma cells. FEBS Lett 1995, 360, 165-168.
56. Ferry DR, Glossmann H, Kauman AG. Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their ability to bind to putative calcium channels in the heart. BrJ Pharmacol 1985, 84, 811-824.
57. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug resistant P388 tumour cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982, 2, 4730-4735.
58. Haussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 1991, 40, 53-59.
59. Plumb J, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant cell lines is not stereo specific. Biochem Pharmacol 1990, 39, 787-791.
60. Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. BrJ Cancer 1991, 64, 1168-1171.
61. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13, 1985-1994.
62. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13, 1995-2004.
63. Lyn PA, Motzer RJ, O'Brien J, Murray LT, Fischer P, Ochoa MJ. Phase I/II trial of velban (VLB) + dexverapamil (DEX) for patients (pts) with advanced renal cell carcinoma (RCC). Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A760.
64. Mickisch GH. Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol 1994, 12, 214-23.
65. Berg S, Tolcher A, O'Shaughnessy JA, et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995, 13, 2039-2042.
66. Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)-, and (±)-verapamil after intravenous administration. Br J Clin Pharmacol 1984, 17, 453-458.
67. 2+ channels and to a sub-type of alpha-1-adrenoceptors. Eur J Pharmacol 1989, 172, 131-145.
68. 3H]-vinblastine binding to P-glycoprotein of MCF-7 ADR breast cancer cell membranes. Biochem Pharmacol 1995, 76, 112-119.
69. Malkhandi PJ, Ferry DR, Boer R, Kerr DJ. P-glycoprotein has a drug acceptor site for 1,4-dihydropyridines which is localised on an intracellular domain. Proc Am Assoc Cancer Res 1995, 36, A332.
70. Gekeler V, Beck J, Boer R, et al. Modulation of P-gp and non-P-gp MDR by the dihydropyridine dexniguldipine-HCl, and GF 109203X, an bisindolylmaleimide exhibiting high selectivity for PKC. Proc Ann Mtg Am Assoc Cancer Res 1994, 35, A2124.
71. Wilisch A, Haussermann K, Noller A, Probst H, Gekeler V. MDR modulating and antineoplastic effects of B859-035, the (-)isomer of niguldipine. J Cancer Res Clin Oncol 1991, 117, S110.
72. Hofmann J, Gekeler V, Ise W, et al. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol 1995, 49, 603-609.
73. Panella TJ, Costanzi JJ, Rathgeb F, Schuller H, Bunn PA. A Phase I trial of oral dexniguldipine (B8509-035) (dNIG) in patients with refractory solid tumors. Proc Ann Mtg Am Soc Clin Oncol 1993, 12, A404.
74. Scheulen M, Nussler V, Kriegmair M, et al. Phase I study of iv dexniguldipine plus vinblastine. Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A419.
75. Dhainaut A, Regnier G, Atassi G, et al. New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 1992, 35, 2481-2496.
76. Leonce S, Pierre A, Anstett M, et al. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol 1992, 44, 1707-1715.
77. Huet S, Chapey C, Robert J. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer 1993, 29A, 1377-1388.
78. Sebille S, Morjani H, Poullain M, Manfait M. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry. Anticancer Res 1994, 14, 2389-2393.
79. Poupon MF, Berlion M, Atassi G, Dunn T, Bizzari JP. S9788, a new resistance modulator, enhances the antitumoral activity of vepesid/cis-platinum treatment on a P-glycoprotein-positive small cell lung cancer xenograft. Proc Ann Mtg Am Assoc Cancer Res 1992, 33, A2796.
80. Awada A, Pagani O, Piccart M, et al. Phase I clinical and pharmacokinetic trials of S9788 alone and in combination with adriamycin (ADM). Proc Ann Mtg Am Assoc Cancer Res 1993, 34, A1274.
81. Glisson BG, Alpeter MA. Comparison of SDZ PSC 833 (PSC) with cyclosporin a (CSA) as resistance modifiers in a multidrug-resistant small cell lung cancer line (meeting abstract). Proc Ann Mtg Am Assoc Cancer Res 1992, 33, A2908.
82. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991, 27, 1639-1642.
83. te Boekhorst PA, van KJ, Schoester M, Sonneveld P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 1992, 30, 238-342.
84. Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enz Regul 1994, 34, 371-380.
85. Keller RP, Altermatt HJ, Nooter K, et al. SDz PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992, 50, 593-597.
86. Fisher GA, Hausdorff J, Lum BL, et al. Phase I trial of etoposide with the cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A368.
87. Giaccone G, Linn SC, Catimel G, et al. Phase I and pharmacokinetic study of SDZ PSC 833 po in combination with doxorubicin in patients with solid tumors. Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A364.
88. Ehrlichman C, Moore M, Thiessen J, De AC, Goodman P, Manzo J. A phase I trial of doxorubicin (D) and PSC833: a modulator of multidrug resistance (MDR). Proc Ann Mtg Am Soc Clin Oncol 1994, 13, A326.
89. Sonneveld P, Marie JP, Laburte C, Schoester M. Phase I study of SDZ PSC833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc Ann Mtg Am Assoc Cancer Res 1994, 35, A2141.
90. Duran GE, Gosland MP, Ho AL, Sikic BI. In vitro modulation of multidrug resistance (MDR) using human patient serum from EP-1: a phase I clinical trial of etoposide (VP-16) and SDZ PSC 833. Proc Ann Mtg Am Assoc Cancer Res 1994, 35, A2093.
91. Chambers TC, Pohl J, Raynor RL, Kuo JF. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 1993, 268, 4592-4595.
92. Meyer T, Regenass Y, Fabbro D, et al. A derivative of staurosporine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative as well as in vivo antitumour activity. Int J Cancer 1989, 43, 851-856.
93. Utz I, Hofer S, Regenass U, et al. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumour activity, reverses multidrug resistance. Int J Cancer 1994, 57, 104-110.
94. Budworth J, Davies R, Malkhandi J, Gant TW, Ferry DR, Gescher A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug resistant MCF-7/Adr cells. Br J Cancer, in press.
95. Hyafil F, Vergely C, Du VP, Grand PT. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53, 4595-4602.
96. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 1993, 11, 2417-2426.
97. Schinkel AH, Smit JJ, van TO, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
98. Kaye SB. P glycoprotein (P-gp) and drug resistance-time for reappraisal? Br J Cancer 1993, 67, 641-643.
99. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993, 11, 1629-1635.
100. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334, 1-6.
101. Eck L, Pavich D, Fruehauf JP. MDR-1 expression by human ovarian tumors is associated with taxol resistance. Proc Ann Mtg Am Assoc Cancer Res 1993, 34, A1388.
102. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81, 116-124.
103. Petrylak DP, Scher HI, Reuter V, O'Brien JP, Cordon CC. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 1994, 5, 835-840.
104. Becker I, Becker KF, Meyermann R, Hollt V. The multidrug-resistance gene mdr1 is expressed in human glial tumors. Acta Neuropathol (Berl) 1991, 82, 516-519.
105. Huang CC, Wu MC, Xu GW, et al. Overexpression of the mdr1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992, 84, 262-264.
106. Kelley DJ, Pavelic ZP, Gapany M, et al. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1993, 119, 411-414.
107. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993, 11, 109-115.
108. Volm M, Mattern J, Samsel B. Overexpression of P-glycoprotein and glutathione S-transferase-π in resistant non-small cell lung carcinomas of smokers. Br J Cancer 1991, 64, 700-704.
109. Darnton SJ, Jenner K, Steyn RS, Ferry DR, Matthews HR. Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. J Clin Path 1995, 48, 1064-1066.
110. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995, 13, 1958-1965.
111. Chan HS, Koren G, Thorner PS, et al. Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cyclosporin A (CsA). Proc Ann Mtg Am Soc Clin Oncol 1992, 11, A1296.
112. Vergier B, Cany L, Bonnet F, Robert J, de M. Coindre JM. Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer 1993, 68, 1221-1226.
113. Pourquier P, Coindre JM, Becouarn Y, Robert J. Analysis of MDR1 (P-glycoprotein) gene expression in human gastric and colorectal adenocarcinomas. Clinical Biology of Cancers, 8th Symposium, April 1993, 55.
114. Bak M, Hanna E, Csokay B, Bodrogi I, Olah E. Multidrug resistance of testicular cancers. Detection of P-glycoprotein and MDR1 gene expression and their clinical connection. Orv Hetil 1995, 136, 19-25.
115. Watanabe M, Sugawara I, Yamashita T, Hasumi K, Masunaga A, Itoyama S. P-glycoprotein expression and the degree of malignancy in anaplastic thyroid carcinoma. Proc Ann Mtg Am Assoc Cancer Res 1993, 34, A1373.
116. Van der Graaf WT, Buter J, De VEG, Willemse PH, Sleijfer DT, Mulder NH. The effect of Amiodarone on cytotoxicity of Adriamycin and Vinca-alkaloids: in vitro data and results of a Phase II study. Proc Ann Mtg Am Assoc Cancer Res 1993, 34, A1267.
117. van Kalken CK, van der Hoven JM, de Jong J, et al. Bepredil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 1991, 27, 739-744.
118. 3H] vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol 1994, 288, 105-114.
119. Philip PA, Joel S, Monkman SC, et al. A phase I study of reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 1992, 65, 267-270.